Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: The automated nonradiometric systems

Journal of Clinical Microbiology

Volumn 44, Issue 1, 2006, Pages 20-28

  Piersimoni, Claudio ^a,d   Olivieri, Armando ^b   Benacchio, Luca ^b   Scarparo, Claudio ^c  

^a United Hospitals   (Italy)

^b Epidemiology Unit   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

^d United Hospitals   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ACCURACY; ANTIBIOTIC SENSITIVITY; AUTOMATION; BACTERIUM CULTURE; BACTERIUM ISOLATE; DEVICE; INOCULATION; INTERMETHOD COMPARISON; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; SHORT SURVEY;

ANTITUBERCULAR AGENTS; AUTOMATION; BACTERIOLOGICAL TECHNIQUES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; REAGENT KITS, DIAGNOSTIC; RIFAMPIN;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS COMPLEX;

EID: 30744462365     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.44.1.20-28.2006     Document Type: Short Survey

References (39)

1. Ådjers-Koskelat, K., and M. L. Katila. 2003. Susceptibility testing with the manual Mycobateria Growth Indicator Tube (MGIT) and the MGIT 960 system provides rapid and reliable verification of multidrug-resistant tuberculosis. J. Clin. Microbiol. 41:1235-1239.
2. American Thoracic Society and Centers for Disease Control and Prevention. 2000. Diagnostic standards and classification of tuberculosis in adults and children. Am. J. Respir. Crit. Care Med. 161:1376-1395.
3. Ångeby, K. A. K., J. Werngren, J. C. Toro, G. Hedström, B. Petrini, and S. E. Hoffner. 2003. Evaluation of the BacT/ALERT 3D system for the recovery and drug susceptibility testing of Mycobacterium tuberculosis. Clin. Microbiol. Infect. 9:1148-1152.
4. Aono, A., K. Hirano, S. Hamasaki, and C. Abe. 2002. Evaluation of BACTEC MGIT 960 PZA medium for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide (PZA): compared with the results of pyrazinamidase assay and Kyokuto PZA test. Diagn. Microbiol. Infect. Dis. 44:347-352.
5. Ardito, F., B. Posteraro, M. Sanguinetti, S. Zanetti, and G. Fadda. 2001. Evaluation of BACTEC Mycobacteria Growth Indicator Tube (MGIT 960) automated system for drug susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 39:4440-4444.
6. Bemer, P., F. Palikova, S. Rüsch-Gerdes, H. B. Drugeon, and G. Pfyffer. 2002. Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 40:150-154.
7. Bemer, P., T. Bodmer, J. Munzinger, M. Perrin, V. Vincent, and H. Drugeon. 2004. Multicenter evaluation of the MB/BacT system for susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 42:1030-1034.
8. Bergmann, J. S., and G. L. Woods. 1998. Evaluation of the ESP culture system II for testing susceptibilities of Mycobacterium tuberculosis isolates to four primary antituberculous drugs. J. Clin. Microbiol. 36:2940-2943.
9. Brunello, F., and R. Fontana. 2000. Reliability of MB/BacT system for testing susceptibility of Mycobacterium tuberculosis complex isolates to anti-tuberculous drugs. J. Clin. Microbiol. 38:872-873.
10. Canetti, G., W. Fox, A. Khomenko, H. T. Maler, N. K. Menon, D. A. Mitchinson, N. Rist, and N. A. Smeiev. 1969. Advances in techniques of testing mycobacterial in tuberculosis control programmes. Bull. W. H. O. 41:21-43.
11. Cochrane Methods Group on Systematic Review of Screening and Diagnostic Tests. 1996. Recommended methods. [Online.] The Cochrane Collaboration, Oxford, United Kingdom, http://www.cochrane.org/docs/sadtdoc1.htm.
12. Diaz-Infentes, M. S., M. J. Ruiz-Serrano, L. Martinez-Sanchez, A. Ortega, and E. Bouza. 2000. Evaluation of the MB/BacT Mycobacterium detection system for susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 38:1988-1989.
13. Espinal, M. A., A. L. Lazslo, L. Simonsen, F. Boulabhal, S. J. Kim, A. Reniero, S. Hoffner, H. L. Rieder, N. Binkin, C. Dye, R. Williams, and M. Raviglione. 2001. Global trends in resistance to anti-tuberculosis drugs. N. Engl. J. Med. 344:1294-1303.
14. Huang, T., H. Tu, S. S. Lee, W. Huang, and Y. Liu. 2002. Antimicrobial susceptibility testing of Mycobacterium tuberculosis to first-line drugs: comparison of the MGIT 960 and BACTEC 460 systems. Ann. Clin. Lab. Sci. 32:142-147.
15. Irwig, L., A. N. Tosteson, C. Gatsonis, J. Lau, T. C. Chalmers, and F. Mosteller. 1994. Guidelines for meta-analyses evaluating diagnostic tests. Ann. Intern. Med. 120:667-676.
16. Johansen, I. S., V. Østergaard, M. Mariamäki, A. Sosnovskaja, and B. Lundgren. 2004. Rapid, automated, nonradiometric susceptibility testing of Mycobacterium tuberculosis complex to first-line antituberculous drugs used in standard short-course chemotherapy. Diagn. Microbiol. Infect. Dis. 50:103-107.
17. Kim, S. J. 2005. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur. Respir. J. 25:564-569.
18. Kontos, F., N. Stavroula, C. Kostopulos, Z. Gitti, E. Petinaki, M. Maniati, S. Anagnostu, A. Raftopoulou, P. Papageorgiu, A. Scrioubellou, I. Tselentis, and A. N. Maniatis. 2003. Multicenter evaluation of the fully automated Bactec MGIT 960 system for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide: comparison with the radiomctric Bactec 460 system. Diagn. Microbiol. Infect. Dis. 55:331-333.
19. LaBombardi, V. J. 2002. Comparison of the ESP and BACTEC system for testing susceptibilities of Mycobacterium tuberculosis complex isolates to pyrazinamide. J. Clin. Microbiol. 40:2238-2239.
20. LaBombardi, V. J. 2004. Versa TREK (formerly ESP culture system II) indirect susceptibility testing for Mycobacterium tuberculosis, p. 7.8.7.1-7.8.7.4. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook, 2nd ed. American Society for Microbiology, Washington, D.C.
21. LaBombardi, V. J. 2004. Versa TREK (formerly ESP culture system II) indirect susceptibility tests with pyrazinamide for Mycobacterium tuberculosis, p. 7.8.8.1-7.8.8.3. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook, 2nd ed. American Society for Microbiology, Washington, D.C.
22. Laszlo, A., M. Rahman, M. Espinal, M. Raviglione, et al. 2002. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998. Int. J. Tuberc. Lung Dis. 6:748-756.
23. Littenberg, B., and L. E. Moses. 1993. Estimating diagnostic accuracy from multiple conflicting reports: a new meta-analytic method. Med. Decis. Making 3:313-321.
24. Madison, B., G. I. Robinson-Dunn, W. Gross, H. Lipman, B. Metchock, A. Sloutsky, G. Washabaugh, G. Mazurek, and J. Ridderhof. 2002. Multicenter evaluation of ethambutol susceptibility of Mycobacterium tuberculosis by agar proportion and radiomctric method. J. Clin. Microbiol. 40:3976-3979.
25. Marttila, H. J., M. Mariamäki, M. K. Viljanene, and H. Soini. 2003. Performance of BACTEC 960 Mycobacteria Growth Indicator Tube in the susceptibility testing of genetically characterized Mycobacterium tuberculosis isolates. Eur. J. Clin. Microbiol. Infect. Dis. 22:757-759.
26. Moses, L. E., D. Shapiro, and B. Littenberg. 1993. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat. Med. 12:1293-1316.
27. National Committee for Clinical Laboratory Standards. 2003. Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes. Approved standard M24-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
28. Park, M. M., A. L. Davies, N. W. Schluger, et al. 1996. Outcome of MDRTB patients, 1983-1993: prolonged survival with appropriate therapy. Am. J. Respir. Crit. Care Med. 153:317-324.
29. Pfyffer, G., F. Palikova, and S. Rüsch-Gerdes. 2002. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system. J. Clin. Microbiol. 40:1670-1674.
30. Roberts, G. D., L. Hall, and D. M. Wolk. 2002. Mycobacteria, p. 256-273. In A. Truant (ed.), Manual of commercial methods in clinical microbiology. American Society for Microbiology, Washington, D.C.
31. Ruiz, P., F. J. Zerolo, and M. J. Casal. 2000. Comparison of susceptibility testing of Mycobacterium tuberculosis using the ESP culture system II with that using the BACTEC method. J. Clin. Microbiol. 38:4663-4664.
32. Sanders, C. A., R. R. Nieda, and E. P. Desmond. 2004. Validation of the use of Midllebrook 7H10, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin. J. Clin. Microbiol. 42:5225-5228.
33. Scarparo, C., P. Ricordi, G. Ruggiero, and P. Piccoli. 2004. Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampin and ethambutol and comparison with the radiometric BACTEC 460TB method. J. Clin. Microbiol. 42:1109-1114.
34. Siddiqi, S. 2004. BACTEC MGIT 960 SIRE. Nonradiometric susceptibility testing for Mycobacterium tuberculosis, p. 7.8.5.1-7.8.5.5. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook, 2nd ed. American Society for Microbiology, Washington, D.C.
35. Siddiqi, S. 2004. BACTEC MGIT 960 PZA. Susceptibility testing for Mycobacterium tuberculosis, p. 7.8.6.1-7.8.6.4. In H. D. Isenberg (ed.), Clinical microbilogy procedures handbook, 2nd ed. American Society for Microbiology, Washington, D.C.
36. Tenover, F. C., J. T. Crawford, R. E. Huebner, L. J. Geiter, C. R. Horsburgh, Jr., and R. C. Good. 1993. The resurgence of tuberculosis: is your laboratory ready? J. Clin. Microbiol. 31:767-770.
37. Tortoli, E., R. Mattei, A. Savarino, L. Bartolini, and J. Beer. 2000. Comparison of Mycobacterium tuberculosis susceptibility testing performed with BACTEC 460TB (Becton Dickinson) and MB/BacT (Organon Teknika) systems. Diagn. Microbiol. Infect. Dis. 38:83-86.
38. Tortoli, E., M. Benedetti, A. Fontanelli, and M. T. Simonetti. 2002. Evaluation of automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to four major antituberculous drugs: comparison with the radiometric BACTEC 460TB method and the agar plate method of proportion. J. Clin. Microbiol. 40:607-610.
39. Yew, W. W., S. C. W. Tong, K. S. Lui, S. K. F. Leung, C. H. Chau, and E. P. Wang. 2001. Comparison of MB/BacT system and agar proportion method in drug susceptibility testing of Mycobacterium tuberculosis. Diagn. Microbiol. Infect. Dis. 39:229-232.